Drugstore.com
This article was originally published in The Tan Sheet
Executive Summary
Online retailer expects record revenues of approximately $70 mil. for the fourth quarter ended Dec. 28, a 28% increase over the prior-year period, firm announces in Jan. 14 preliminary earnings release. OTC sales should account for 52% of the sales growth in the quarter. "In a very tough economy, we have been a high-growth retailer that has consistently outperformed the competition," stated President & CEO Kal Raman. "We are now well-positioned to capitalize on the incredible growth opportunities in the $273 bil. health, beauty, wellness and pharmacy market." The firm will announce its fiscal year 2003 results Jan. 20...
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.